Search Results

Elicio Therapeutics, Inc. announced new preliminary data from the ongoing AMPLIFY-7P Phase 1a study of its off-the-shelf investigational therapeutic cancer vaccine candidate, ELI-002 7P.

7 Hills Pharma Inc., a clinical-stage pharma company leveraging a novel mechanism of action to safely enhance the effectiveness of cancer immunotherapies, was awarded $4.7 million from the Cancer Prevention and Research Institute of Texas to support its cell/gene therapy development program.

Dioseve Inc., aiming to develop assisted reproductive technology using oocytes derived from iPS cells, has raised 7 million USD.

Shanghai MicuRx Pharmaceutical Co., Ltd. announced 3 new studies will be presented at the 7th World Bronchiectasis Conference, taking place from July 4 - 6, 2024 in Dundee, Scotland.

Future Pak LLC (“Future Pak”) today announced that it has submitted three proposals since February to acquire all of the outstanding shares of common stock of Vanda Pharmaceuticals, Inc. (“Vanda”) (NASDAQ: VNDA), and confirms that its most recent proposal to acquire Vanda for cash consideration of $7.25 to $7.75 per share remains open for Vanda and its Board of Directors to consider.

Raydiant Oximetry, Inc., a clinical-stage medical device company that develops medical technologies to improve outcomes for mothers and babies during childbirth, announced that it has oversubscribed a $7.5 million Series A3 extension round.

The pancreatic cancer market size grew to USD 2.05 billion in 2022 and is estimated to hit approximately USD 7.4 billion by 2032, with a CAGR of 13.7% for the period of 2023 – 2032.

Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”) today announced preliminary data from the ongoing AMPLIFY-7P Phase 1a study of its off-the-shelf investigational therapeutic cancer vaccine candidate, ELI-002 7P, in a poster presentation at the American Society of Clinical Oncology (“ASCO”) Annual Meeting.

PharmaCyte Biotech, Inc. today announced a $7 million investment in MyMD Pharmaceuticals, Inc.

Tandem Diabetes Care, Inc. and Dexcom, Inc., announced that the Tandem Mobi insulin pump with Control-IQ technology is now fully compatible with both the Dexcom G7 and Dexcom G6 Continuous Glucose Monitoring Systems.